All In Biotech

Drug Trial Radar · NCT01196260

Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III

Clinical Trial on Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III Among Chinese Population

Last checked: Nov 19, 2026Latest source record: Feb 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 8,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

8,000

Planned (sponsor's estimate)

Start

Jan 2004

Primary completion

Dec 2020

Study completion Dec 2020

Sponsor

Lead sponsor
State Key Laboratory of Cancer BiologyResearch network
Sponsor type
Research network
Collaborators
Tianjin Union Medical Center; Beihua University; Chengdu Medical College; Shanghai Jiao Tong University School of Medicine
First posted
Sep 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine a new combination of drugs: Capecitabine and Oxaliplatin for the treatment of Stage II and III colorectal cancer. Capecitabine and Oxaliplatin are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination has a positive effect on metastatic colorectal cancer.

Conditions

  • Colorectal Cancer

Interventions

  • Capecitabine and OxaliplatinDrug

    Capecitabine and Oxaliplatin will be under the NSCLC guideline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the objective response rate of patients with metastatic colorectal cancer received the combination of drugsTime frame: 7 years
  2. To determine the relapse of patients with metastatic colorectal cancer received the combination of drugsTime frame: 7 years
  3. To determine prognosis of patients with metastatic colorectal cancer received the combination of drugsTime frame: 7 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • State Key Laboratory of Cancer Biology

    Xi'an, Shaanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.